Teriparatide Induced Delayed Persistent Hypercalcemia
Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persi...
Saved in:
| Main Authors: | Nirosshan Thiruchelvam, Jaskirat Randhawa, Happy Sadiek, Gaurav Kistangari |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/802473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Persistent Hypercalcemia and Hyperparathyroidism in a Horse
by: Claudia Cruz Villagrán, et al.
Published: (2014-01-01) -
Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
by: Ikuko Tanaka, et al.
Published: (2013-01-01) -
Prolonged Hypercalcemia-Induced Psychosis
by: Lauren Nagy, et al.
Published: (2020-01-01) -
Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis
by: Huan Jin, et al.
Published: (2025-05-01) -
Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
by: Tiffany T. Oommen, et al.
Published: (2023-01-01)